Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 19% of the time (731 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: tolerabilitysubjectslong termmriterm safety
  Phrases that lowered it: mglabelopenparallelreceive
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 16.6% (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 352 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Phase: 2 (raises risk) · Design
• Sponsor's past trials: 571 (raises risk) · Sponsor's track record
• Minimum age: 50 (raises risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: none (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 89 (lowers risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 1 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study Evaluating Bapineuzumab In Alzheimer Disease Subjects NCT00663026 · started 2008 · scored riskier than 94% of active trials completed
• Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease NCT01369225 · started 2011 · scored riskier than 99% of active trials completed
• Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease NCT01254773 · started 2010 · scored riskier than 67% of active trials completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease NCT00937352 · started 2009 · scored riskier than 99% of active trials terminated
• Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease NCT01193608 · started 2010 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.